Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer

Area of Science:

• Oncology
• Pharmacology
• Medicinal Chemistry

Background:

• Prostate cancer, particularly advanced forms like castration-resistant prostate cancer (CRPC) and castration-sensitive prostate cancer (CSPC), presents significant therapeutic challenges.
• The androgen receptor (AR) signaling pathway is a critical driver in prostate cancer progression.
• First-generation anti-androgens have limitations in efficacy and resistance development.

Purpose of the Study:

• To review the rational design, discovery, and development of second-generation nonsteroidal AR antagonists.
• To highlight the synthesis, clinical studies, and therapeutic applications of enzalutamide, apalutamide, and darolutamide.
• To explore strategies for overcoming resistance to these advanced AR antagonists in prostate cancer treatment.

Main Methods:

• Review of scientific literature focusing on drug discovery, preclinical studies, and clinical trials of second-generation AR antagonists.
• Analysis of the chemical design principles leading to enhanced AR binding affinity and inhibitory activity.
• Examination of FDA approval data and clinical outcomes for enzalutamide, apalutamide, and darolutamide in various prostate cancer stages.

Main Results:

• Enzalutamide, the first second-generation AR antagonist, demonstrates significant improvements in overall survival, metastatic-free survival, and castration-resistant-free survival for CRPC and CSPC.
• Subsequent FDA approvals of apalutamide and darolutamide validate the therapeutic potential of second-generation AR antagonists across advanced prostate cancer.
• These agents effectively target AR signaling, offering a crucial hormonal therapy option for multiple forms of advanced prostate cancer.

Conclusions:

• Second-generation AR antagonists represent a major advancement in prostate cancer therapy, providing effective hormonal treatment options.
• The success of enzalutamide, apalutamide, and darolutamide underscores the importance of targeting the AR pathway in advanced prostate cancer.
• Ongoing research into overcoming resistance mechanisms is vital for maximizing the long-term efficacy of these therapies.